Paratek Pharmaceuticals, which is based in Boston but has offices in King of Prussia, is turning private after being a publicly traded company for almost nine years, writes John George for Philadelphia Business Journal.

The biopharmaceutical firm has agreed to be acquired by Gurnet Point Capital, a health care investment firm, and Novo Holdings A/S, an investment firm that manages the assets of the Novo Nordisk Foundation.

The deal is reported to be valued at about $462 million.

The company said in documents filed with the Securities and Exchanges Commission that the decision “is the result of a months-long process of exploring strategic considerations for the company and discussions with a number of external parties who expressed interest in Paratek and Nuzyra.”

Nuzyra is an antibiotic approved to treat community-acquired bacterial pneumonia and certain acute skin infections.

As of right now, there are no plans to close its King of Prussia offices at 1000 First Ave.

Read more about the agreement in the Philadelphia Business Journal.

_________________

Learn more about Nuzyra.